关键词: 糖尿病,2型, 代谢综合征, 钠-葡萄糖共转运蛋白2抑制剂, 利拉鲁肽

Abstract:

Objective To investigate the clinical efficacy of dapagliflozin combined with liraglutide in the treatment of type 2 diabetes mellitus(T2DM) with metabolic syndrome.Methods Fifty-two T2DM patients concurrent with metabolic syndrome were selected and randomly divided into the control group (n=26) and the observation group (n=26), according to 1∶1.The control group was treated with liraglutide, and the observation group was additionally treated with dapagliflozin on the basis of the control group.The course of treatment was 12 weeks. The changes of related indicators were compared before and after treatment in two groups.Results After treatment, the blood glucose metabolism index, islet function index, body mass index, waist circumference, blood pressure, blood lipids in both groups were improved(P<0.05). The levels of fasting blood glucose, 2 h postprandial blood glucose, glycosylated hemoglobin, insulin resistance index,body mass index, waist circumference, systolic blood pressure, diastolic blood pressure, total cholesterol, triglycerides in the observation group were significantly decreased compared with the control group after treatment(P<0.05), and high-density lipoprotein cholesterol, fasting insulin and pancreatic β cell function index were significantly increased(P<0.05), while low-density lipoprotein cholesterol had no difference(P>0.05). There was no statistical difference in the incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion The combination of dapagliflozin and liraglutide for T2DM concurrent with metabolic syndrome can effectively control blood sugar, reduce weight, improve obesity, regulate blood pressure and lipid metabolism, reduce insulin resistance and improve islet function, and have good safety.

Key words: diabetes mellitus,type 2, metabolic syndrome, sodium-glucose transporter 2 inhibitors, liraglutide